FIELD: pharmacology.
SUBSTANCE: invention relates to a compound of formula
(I)
or a pharmaceutically acceptable salt thereof, wherein Q is O; W is phenyl; X is absent; Y is NH; Z1 and Z2 are N; Z3 is NR5, where R5 is hydrogen; R1 is pyridine or pyrimidine; optionally substituted with C1-C6alkyl, C1-C6alkoxy, -NR10R11 or -SOmR12, where R10 and R11 are hydrogen, R12 is C1-C6alkyl; and m is 0; R3 is C1-C6alkyl; R2 is C1-C6alkyl when p is 1; or one R2 is C1-C6alkyl and one R2 is halogen when p is 2; or one R2 and R3 combined with formation of a five- to seven-membered carbocycle; R4 is hydrogen; p=1 or 2; and n is 1.
EFFECT: heterocyclic compounds designed for cancer treatment.
12 cl, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONDENSED BICYCLIC COMPOUNDS FOR TREATING DISEASE | 2015 |
|
RU2706007C2 |
| ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2707749C2 |
| COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | 2019 |
|
RU2795108C2 |
| COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | 2018 |
|
RU2786719C2 |
| BRIDGED N-CYCLYC SULPHONAMIDO-INHIBITORS OF GAMMA-SECRETASE | 2006 |
|
RU2422443C2 |
| MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
| HISTONE DEACETYLASE INHIBITORS | 2014 |
|
RU2673819C2 |
| APPLICATION OF 2-(2-NITRO-4-TRIFLUORMETHYLBENZOYL)-1,3-CYCLOHEXANDIONE IN TREATMENT OF PARKINSON'S DISEASE | 2006 |
|
RU2420272C2 |
| COURSE OF TREATMENT WITH APPLICATION OF RECEPTOR S1P AGONIST | 2005 |
|
RU2478384C2 |
| COMPOUNDS | 2016 |
|
RU2734877C2 |
